Efficacy and safety of rhGH in juvenile dermatomyositis children with glucocorticoid-related growth failure
In JDM patients with growth failure, rhGH therapy may be considered as a potential treatment option, supported by preliminary evidence. Our study suggests an acceptable safety profile and potential efficacy in improving growth parameters, even in refractory cases. Further larger-scale multicentre studies will be necessary to confirm its application value in JDM.
Authors
- Baozhen Huang (ORCID: https://orcid.org/0000-0002-2377-5568)
- Guangxu Ren (ORCID: https://orcid.org/0000-0003-2378-260X)
- Xiaolei Wang (ORCID: https://orcid.org/0000-0003-4373-6061)
- Yuan Liu (ORCID: https://orcid.org/0000-0003-2668-0350)
- Xinning Wang (ORCID: https://orcid.org/0000-0002-7022-8073)
- Jianguo Li (ORCID: https://orcid.org/0000-0001-9431-2950)
- Qian Jiang
Institutions
- City University of Hong Kong (HK)
- Capital Medical University (CN)
- Center for Children (US)
- Capital Institute of Pediatrics (CN)
- Beijing Children’s Hospital (CN)
- Ministry of Agriculture and Rural Affairs (CN)
Publication Details
- Journal
- Lara D. Veeken
- Published
- 2025-06-17
- DOI
- https://doi.org/10.1093/rheumatology/keaf236
- Citations
- 1
- Primary Topic
- Inflammatory Myopathies and Dermatomyositis
- Type
- article
- Field-Weighted Citation Impact
- 1.35